Nautilus Biotechnology Inc
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
NAUT$2.32-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
Nautilus Biotechnology, Inc.Consolidated Statements of Comprehensive LossYears Ended December 31, 2023 and 2022
| (in thousands) | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|
| Net loss | $(63,675) | $(57,924) |
| Other comprehensive income (loss): | ||
| Unrealized gain (loss) on securities available-for-sale | 1,599 | (1,670) |
| Total other comprehensive income (loss) | 1,599 | (1,670) |
| Comprehensive loss | $(62,076) | $(59,594) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.